CTOs on the Move


 
Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research. We are headquartered in Cambridge UK. Our eight additional sales, production, and distribution offices are located in Asia, UK, and the USA.   Our mission is to help scientists to discover more. Our vision is to be the brand most recommended by life science researchers.   We recognise the importance of providing clear and timely information to our existing and potential ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.abcam.com
  • 1 Kendall Sq
    Cambridge, MA USA 02139
  • Phone: 617.225.2272

Executives

Name Title Contact Details

Similar Companies

Source MDx

Source MDx is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

northwest radiography ps

northwest radiography ps is a Federal Way, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamond Diagnostics

Diamond Diagnostics is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pentron Clinical Technologies

Pentron Clinical Technologies is a Wallingford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gritstone Oncology

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.